Lumexa Imaging (NASDAQ:LMRI) Updates FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.710-0.770 for the period, compared to the consensus estimate of 0.620. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Lumexa Imaging Stock Performance

Lumexa Imaging stock traded up $0.07 during trading hours on Wednesday, hitting $11.73. The company had a trading volume of 735,578 shares, compared to its average volume of 790,443. The firm has a 50-day moving average of $10.62 and a 200 day moving average of $10.94. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.40 and a quick ratio of 1.40. The firm has a market cap of $1.13 billion and a PE ratio of -19.88. Lumexa Imaging has a one year low of $6.45 and a one year high of $19.45.

Lumexa Imaging (NASDAQ:LMRI) last posted its earnings results on Wednesday, August 12th. The company reported $0.20 EPS for the quarter. The firm had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. On average, sell-side analysts expect that Lumexa Imaging will post 0.27 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LMRI. Wall Street Zen cut shares of Lumexa Imaging from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings upgraded shares of Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research note on Thursday, June 25th. Finally, Barclays cut their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Insider Buying and Selling at Lumexa Imaging

In other news, Director Brett Brodnax purchased 35,000 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was bought at an average price of $7.25 per share, with a total value of $253,750.00. Following the acquisition, the director owned 62,027 shares in the company, valued at approximately $449,695.75. The trade was a 129.50% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Lumexa Imaging

Several institutional investors and hedge funds have recently added to or reduced their stakes in LMRI. Barclays PLC acquired a new position in Lumexa Imaging during the fourth quarter worth about $133,000. Sandia Investment Management LP acquired a new stake in shares of Lumexa Imaging in the 4th quarter valued at approximately $185,000. Hudson Bay Capital Management LP acquired a new stake in shares of Lumexa Imaging in the 4th quarter valued at approximately $237,000. Oxford Asset Management LLP bought a new stake in shares of Lumexa Imaging during the 4th quarter valued at approximately $670,000. Finally, Burkehill Global Management LP bought a new stake in shares of Lumexa Imaging during the 4th quarter valued at approximately $925,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).